Search Results
Your search for Jo Cavallo matches 17 pages
Showing 1 - 17Lack of Clinical Trial Participation and Shorter Duration of Therapy Linked to Disease Relapse in AYAs With Leukemia
Despite survival gains for children diagnosed with acute lymphoblastic leukemia (ALL), adolescents and young adults (AYAs)—those between the ages of 15 and 39—diagnosed with the disease have seen only modest improvements in survival. A study by Wolfson et al in Cancer Epidemiology,...
Neonatal Dysregulated Immune Function and Pediatric B-Cell Precursor ALL
A high incidence of clinically diagnosed infections in the first year of life among children who later developed acute lymphoblastic leukemia (ALL) has led researchers to propose that children with ALL are born with a dysregulated immune function, resulting in a more vigorous reaction to infections ...
Study Finds Hispanic Pediatric Patients at Increased Risk of Methotrexate Neurotoxicity During Treatment for ALL
Case studies have reported a high prevalence of methotrexate subacute neurotoxicity among Hispanic adolescents with acute lymphoblastic leukemia (ALL), suggesting sensitivity to methotrexate therapy may differ by race and ethnicity. Now, a prospective study in pediatric patients with ALL has found...
Fat Cells May Inactivate Chemotherapeutic Drug and Contribute to Poorer Survival in ALL
It is well established that obesity increases the risk for cancer mortality, although no mechanisms have been proven to explain the reason for this association. Now a laboratory study investigating how obesity might alter the effectiveness of daunorubicin in the treatment of acute lymphoblastic...
Study Finds Venetoclax Monotherapy Safe and Clinically Active in AML
A phase II study has found venetoclax (Venclexta) to be clinically active in patients with high-risk relapsed/refractory acute myelogenous leukemia (AML) or those unfit for intensive chemotherapy, with an overall response rate of 19% and a tolerable safety profile. The study results, which were...
Increased Risk for Cardiovascular Events Seen in Patients With CML Taking Tyrosine Kinase Inhibitors
Although tyrosine kinase inhibitors have dramatically increased survival for patients with chronic myeloid leukemia (CML), continuous administration of these drugs may elicit long-term toxicity, including cardiovascular adverse events. To investigate the incidence of vascular events in patients...
'Matriarch of Modern Cancer Genetics,' Janet D. Rowley, MD, Helped Propel the Field of Molecular Oncology
Even as a child, Janet D. Rowley, MD, found the intellectual order and logic of science appealing. Born on April 5, 1925, in New York, Dr. Rowley’s parents, Hurford and Ethel Ballantyne Davison, moved the family to Chicago 2 years later. Both educators, the Davisons encouraged their only child in...
Study Identifies Splicing Alterations That Enable Resistance to CD19 CAR T-Cell Immunotherapy
Although the CD19 antigen expressed on most B-cell acute lymphoblastic leukemias (ALL) can be targeted with chimeric antigen receptor–armed T cells (CART-19), relapse rates among pediatric and adult patients with the cancer remain high. In this study by Sotillo et al, the researchers...
Researchers Identify Dozens of Genetic Mutations Driving CLL and Their Evolution in Progression and Relapse
An analysis of whole-exome sequencing data from 538 patients with chronic lymphocytic leukemia (CLL), including 278 pretreatment samples collected from patients enrolled in a clinical trial, has identified 44 recurrently mutated genes and 11 recurrent somatic copy number variations. These findings...
Chemotherapy Pretreatment May Boost Effectiveness of CAR T-Cell Therapy in Patients With Lymphoma and Leukemia
A small phase I/IIa study of third-generation CD19 CAR (chimeric-antigen receptor) T-cell therapy combined with chemotherapy pretreatment has resulted in complete responses in 6 of the 11 patients with relapsed or refractory lymphoma and leukemia enrolled in the study. Although CAR T-cell...
Preclinical Studies Demonstrate Activity of Type II JAK2 Inhibitor in B-Cell ALL
Laboratory and animal tests of the type II inhibitor CHZ868, which stabilizes the kinase domain in an inactive conformation, are showing that the compound is highly potent against B-cell acute lymphoblastic leukemias (ALLs) with CRLF2 rearrangements. When combined with dexamethasone, CHZ868 induced ...
Exposure to Hookah Smoke Doubles Benzene Uptake, Potentially Increasing Risk for Leukemia
Findings from a new study show that hookah smokers and nonsmokers exposed to hookah (or waterpipe) secondhand tobacco smoke at social events in hookah lounges and in private homes had significant increases in uptake of benzene, a leukemogen that causes lymphohematopoietic cancers, especially acute...
Tyrosine Kinase Inhibitors May Improve Treatment Outcomes in Children With Philadelphia Chromosome–Like ALL
Using genomic profiling and next-generation sequencing of patients with BCR-ABL1-like B-progenitor acute lymphoblastic leukemia (B-cell ALL) and Philadelphia chromosome–like ALL, researchers recently identified alterations targeting 18 kinase or cytokine receptor genes. They then determined...
Investigational Bromodomain Inhibitor Shows Clinical Activity in Some Blood Cancers
The results from a phase I study of a new investigational epigenetic therapy called OTX015, a small-molecule inhibitor that blocks the activity of bromodomain and extraterminal (BET)-bromodomain proteins, is showing clinical activity in some blood cancers, including leukemia and lymphoma. The study ...
Normal Enzyme Pairs With Mutated FLT3 to Fuel AML Progression
Findings from a study by Puissant et al suggest that the wild-type form of enzyme SYK pairs with FLT3, the most commonly mutated enzyme found in acute myeloid leukemia (AML), to promote progression of the cancer. The molecular partnership also promotes AML cells’ resistance to treatment with...
Study Identifies Functional Cooperative Mutations of SETD2 in the Development of Acute Leukemia
Using data from the whole-genome sequencing of a pair of 3-year-old female monozygotic twins, one healthy and one with the multilineage form of acute myeloid leukemia (AML), a team of scientists from China and the United States have identified a novel molecular target that could offer a new...
Lab-Grown Stem Cell–Derived T Cells Fight Cancer in Tumor-Bearing Mice
Although small clinical studies of adoptive T-cell therapy in the treatment of advanced forms of leukemia have shown positive results, including putting some patients into complete remissions, progress in the development of this type of immunotherapy is limited by the lack of readily available,...
